Pre-ART HIV resistance testing in Africa: are we there yet?

Affiliations

Comment

Andrew Kambugu. Lancet Infect Dis. 2012 Apr.

. 2012 Apr;12(4):261.

doi: 10.1016/S1473-3099(11)70280-8. Epub 2011 Oct 27.

¹ Infectious Diseases Institute, Makerere University College of Health Sciences, Box 22418, Kampala, Uganda. akambugu@idi.co.ug

No abstract available

Comment on

Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study.
Hamers RL, Schuurman R, Sigaloff KC, Wallis CL, Kityo C, Siwale M, Mandaliya K, Ive P, Botes ME, Wellington M, Osibogun A, Wit FW, van Vugt M, Stevens WS, de Wit TF; PharmAccess African Studies to Evaluate Resistance (PASER) Investigators. Hamers RL, et al. Lancet Infect Dis. 2012 Apr;12(4):307-17. doi: 10.1016/S1473-3099(11)70255-9. Epub 2011 Oct 27. Lancet Infect Dis. 2012. PMID: 22036233 Clinical Trial.